Moderna
Moderna price
About Moderna
Moderna, Inc., ett bioteknikföretag, är dedikerat till upptäckt, utveckling och kommersialisering av terapier baserade på budbärar-RNA (mRNA) och förebyggande läkemedel. Dess omfattande forsknings- och utvecklingsinsatser riktar sig mot ett brett spektrum av medicinska behov, inklusive infektionssjukdomar, cancerimmunologi, sällsynta tillstånd, hjärt-kärlsjukdomar och autoimmuna sjukdomar, med verksamhet i USA, Europa och andra globala marknader. Företagets mångsidiga produktpipeline omfattar olika vaccinkandidater: de för luftvägssjukdomar som COVID-19, influensa och respiratoriskt syncytialvirus (RSV); latenta virusinfektioner såsom cytomegalovirus (CMV), Epstein-Barr-virus (EBV), humant immunbristvirus (HIV), herpes simplex-virus (HSV) och varicella-zoster-virus (VZV); samt folkhälsohot som Zika och Nipah. Dessutom främjar Moderna systemiska sekreterade och cellytariktade terapier, en rad cancervacciner (inklusive personaliserade, KRAS och checkpoint-varianter), intratumörala immunoonkologiprodukter, lokaliserade regenerativa behandlingar, systemiska intracellulära läkemedel och inhalerade lunglösningar. Moderna upprätthåller strategiska allianser med flera framstående aktörer, inklusive AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, Carisma Therapeutics, Inc., Metagenomi, Inc., Defense Advanced Research Projects Agency (DARPA), Biomedical Advanced Research and Development Authority (BARDA), Institute for Life Changing Medicines och The Bill & Melinda Gates Foundation. Det har också ett samarbets- och licensavtal med Chiesi Farmaceutici S.P.A. Grundat 2010 som Moderna Therapeutics, Inc., blev företaget officiellt Moderna, Inc. i augusti 2018. Företagets huvudkontor ligger i Cambridge, Massachusetts.
- Aktieticker
- MRNA
- Företag
- Moderna, Inc.
- Industri
- Sjukvård
- Kategori
- US
- Aktiesplit / omvänd split
- --
- Lanseringsdatum
- 7 dec. 2018
- Listad börs
- NASDAQ
Finansiellt
Sammanfattning: MRNA reported Revenue of 145.00M (+2,11 %), beating expectations; EPS of −1,97 (+7,51 %), beating expectations.
Moderna conversion tables
 |  |
|---|---|
| 0.5 MRNA | 84,47 EUR |
| 1 MRNA | 168,94 EUR |
| 5 MRNA | 844,7 EUR |
| 10 MRNA | 1 689,4 EUR |
| |
|---|---|
| 0.5 EUR | 0,0029596 MRNA |
| 1 EUR | 0,0059193 MRNA |
| 5 EUR | 0,029596 MRNA |
| 10 EUR | 0,059193 MRNA |
More to explore
FAQ
MRNA is trading at €168,94, −6,40 % over the last 24 hours. Track live moves on the price chart at the top of this page.
The MRNA stock forecast depends on a mix of factors — broader market conditions, sector trends, and company-specific drivers like earnings, product cycles, and macro signals. MRNA is currently trading at €168,94, −6,40 % over the last 24 hours, which reflects how the market is pricing these factors today. For a longer-term outlook on MRNA price action, review the 30-day, 60-day, and 90-day performance shown above, monitor momentum across the Sjukvård sector, and watch overall market sentiment. Stock forecasts and price predictions are inherently uncertain — always DYOR.
P/E ratio (Price-to-Earnings, trailing twelve months) measures how much investors pay per dollar of earnings over the last 12 months. MRNA's P/E ratio is currently -- — calculated by dividing its share price by its trailing 12-month earnings per share (EPS). A higher P/E suggests investors expect stronger future growth from MRNA; a lower P/E may indicate the stock is undervalued or that the market is pricing in a weaker outlook. P/E ratios are most useful when compared against MRNA's historical range and other companies in the Sjukvård sector.
Moderna, Inc.'s market cap is currently 67,44 md EUR. Market cap is calculated as stock price × total shares outstanding.
Disclaimer
The social content on this page ("Content"), including but not limited to tweets and statistics provided by LunarCrush, is sourced from third parties and provided "as is" for informational purposes only. OKX does not guarantee the quality or accuracy of the Content, and the Content does not represent the views of OKX. It is not intended to provide (i) investment advice or recommendation; (ii) an offer or solicitation to buy, sell or hold digital assets; or (iii) financial, accounting, legal or tax advice. Digital assets, including stablecoins and NFTs, involve a high degree of risk and can fluctuate greatly. The price and performance of the digital assets are not guaranteed and may change without notice.
OKX does not provide investment or asset recommendations. You should carefully consider whether trading or holding digital assets is suitable for you in light of your financial condition. Please consult your legal/tax/investment professional for questions about your specific circumstances. For further details, please refer to our Terms of Use and Risk Warning.